Answers are grounded in this paper and cite their sources.
A double-blind trial comparing the effect of Permixon (160 mg bd) against placebo in the treatment of benign prostatic hypertrophy is described. In both groups a significant improvement in flow rate and subjective assessment of symptoms was seen. There was no significant difference between the results of treatment in either group.
No takes yet. Share an insight, caveat, or question.
SMITH et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: